Combined HMAs/DLI can not only reduce the incidence of GvHD, the major complication of DLI in the treatment of relapsed AML after allo-HSCT (approximately 40% of patients develop GvHD after DLI) (82), but also enhance the immunomodulatory role, such as increasing the response of CD8+ T cells (45, 84). Here, CD8A is linked to graft versus host disease.